
Asahi Kasei Life Science Licenses Novel ADC Technology From The Noguchi Institute
Asahi Kasei Life Science has acquired the license rights for a
novel antibody-drug conjugate (ADC) technology from The Noguchi Institute.

Asahi Kasei Life Science has acquired the license rights for a
novel antibody-drug conjugate (ADC) technology from The Noguchi Institute.

MSD receives a non-exclusive license for Cyprumed's drug delivery technology for developing oral peptide therapeutics.

ECI Group recently announced the signing of a licensing agreement with Shaanxi Yanchang China Coal Yulin Energy & Chemical Co., Ltd. (YECC) to deliver a 150kta copolymer plant project using ECI Group’s proprietary hybrid reactor technology.

